Diagnostic assay for cancer susceptibility
AssigneeOklahoma Medical Research Foundation
InventorsEldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
Life of this patent
Estimating the term…
Abstract
The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
Claims41
A method for determining risk of cancer other than breast cancer comprising the steps of:
- a) determining the base identity of a portion of genomic DNA from a patient cell sample, said genomic DNA comprising a prohibitin gene comprising a 3′ untranslated region, said portion corresponding to position 729 as defined in SEQ ID NO:1 of said prohibitin gene in said untranslated region;
- and
- b) correlating said base identity at position 729 as defined in SEQ ID NO:1 of said genomic DNA with germline polymorphisms at position 729 indicative of a risk for said cancer.
A method for determining the risk for cancer other than breast cancer in a human patient, comprising the steps of:
- a) determining the sequence of RNA isolated from said patient in a region which is a transcription of a portion of genomic DNA, said genomic DNA comprising a prohibitin gene comprising a 3′ untranslated region, said portion corresponding to position 729 as defined in SEQ ID NO:1 of said prohibitin gene in said untranslated region;
- and
- b) correlating said base identity at position 729 as defined in SEQ ID NO:1 of said genomic DNA with germline polymorphisms at position 729 indicative of a risk for said cancer.
Dependencies are inferred from the claim text.